STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] Apogee Therapeutics, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Andrew Gottesdiener, Director at Apogee Therapeutics, received a stock option grant to purchase 14,461 shares of common stock at an exercise price of $41.66 per share on June 17, 2025.

Key details of the option grant:

  • Exercise price: $41.66 per share
  • Vesting: 100% on one-year anniversary of grant date
  • Expiration date: June 17, 2035
  • Subject to continued service with the company

Notable arrangement: The options are held under an agreement with VR Management, LLC, where Gottesdiener must exercise the options solely at their direction. VR Management is entitled to the underlying shares, with Gottesdiener disclaiming beneficial ownership except for his pecuniary interest.

Positive
  • None.
Negative
  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Gottesdiener Andrew

(Last) (First) (Middle)
C/O APOGEE THERAPEUTICS, INC.
221 CRESCENT ST., BLDG. 17, STE. 102B

(Street)
WALTHAM MA 02453

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Apogee Therapeutics, Inc. [ APGE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/17/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $41.66 06/17/2025 A 14,461 (1) 06/17/2035 Common Stock 14,461 $0.00 14,461 D(2)
Explanation of Responses:
1. This option represents the right to purchase 14,461 shares of the Issuer's common stock and will vest on the one-year anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer on such vesting date.
2. Under an agreement between the Reporting Person and VR Management, LLC (the "Management Company"), the Reporting Person is deemed to hold the reported option and the shares underlying the option for the sole benefit of the Management Company and must exercise the reported option solely upon the direction of the Management Company, which is entitled to the shares underlying the option. The Management Company may be deemed the indirect beneficial owner of the shares underlying the option, and the Reporting Person may be deemed the indirect beneficial owner of the reported shares underlying the option through his interest in the Management Company. The Reporting Person disclaims beneficial ownership of the reported shares except to the extent of his pecuniary interest therein.
/s/ Matthew Batters, as attorney-in-fact for Andrew Gottesdiener 06/20/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What stock options did APGE director Andrew Gottesdiener receive on June 17, 2025?

Andrew Gottesdiener received stock options to purchase 14,461 shares of APGE common stock at an exercise price of $41.66 per share. The options will vest on the one-year anniversary of the grant date (June 17, 2026), subject to his continued service with the company.

When do Andrew Gottesdiener's APGE stock options expire?

The stock options granted to Andrew Gottesdiener expire on June 17, 2035, which is 10 years from the grant date.

What is the special arrangement between APGE director Gottesdiener and VR Management regarding his stock options?

Under an agreement with VR Management, LLC, Gottesdiener holds the options for the sole benefit of the Management Company and must exercise them only upon their direction. VR Management is entitled to the underlying shares and may be deemed the indirect beneficial owner, while Gottesdiener disclaims beneficial ownership except for his pecuniary interest.

What is the exercise price of APGE stock options granted to director Gottesdiener in June 2025?

The stock options were granted with an exercise price of $41.66 per share.
Apogee Therapeutics Inc

NASDAQ:APGE

APGE Rankings

APGE Latest News

APGE Latest SEC Filings

APGE Stock Data

3.88B
61.87M
7.59%
132.45%
15.44%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
WALTHAM